Evidence map›Paper›PMID 39164747›Full record

ReviewJournal of nanobiotechnology2024

Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system.

Wei Liu, Lubin Liu, Hong Li, Yutong Xie, Ju Bai, Jialiang Guan, Hongzhao Qi, Jinping Sun

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei Liu *Department of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Lubin Liu *Department of Stomatology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Hong LiClinical Laboratory, Qingdao Traditional Chinese Medicine Hospital (Qingdao Hiser Hospital), Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, 266033, China.
Yutong XieDepartment of Stomatology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Ju BaiDepartment of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Jialiang GuanDepartment of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Hongzhao QiInstitute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, 266021, China. qihongzhao@qdu.edu.cn.
Jinping SunDepartment of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. sunjinping@qdu.edu.cn.

Funding

National Key Research and Development Project of China 2018YFC1315200the National Nature Science Foundation of China 52103170the National Research and Development Program of China 2017YFC1307701the traditional Chinese Medicine Science and Technology Project of Qingdao 2022-zyyz07
6 · The paper itself

Abstract

Ischemic stroke poses significant challenges in terms of mortality and disability rates globally. A key obstacle to the successful treatment of ischemic stroke lies in the limited efficacy of administering therapeutic agents. Leveraging the unique properties of nanoparticles for brain targeting and crossing the blood-brain barrier, researchers have engineered diverse nanoparticle-based drug delivery systems to improve the therapeutic outcomes of ischemic stroke. This review provides a concise overview of the pathophysiological mechanisms implicated in ischemic stroke, encompassing oxidative stress, glutamate excitotoxicity, neuroinflammation, and cell death, to elucidate potential targets for nanoparticle-based drug delivery systems. Furthermore, the review outlines the classification of nanoparticle-based drug delivery systems according to these distinct physiological processes. This categorization aids in identifying the attributes and commonalities of nanoparticles that target specific pathophysiological pathways in ischemic stroke, thereby facilitating the advancement of nanomedicine development. The review discusses the potential benefits and existing challenges associated with employing nanoparticles in the treatment of ischemic stroke, offering new perspectives on designing efficacious nanoparticles to enhance ischemic stroke treatment outcomes.

Indexed as

Blood-Brain BarrierDrug Delivery SystemsIschemic StrokeNanoparticlesAnimalsBrainBrain IschemiaHumansNanomedicineNanoparticle Drug Delivery SystemNeuroprotective AgentsOxidative StressNanoparticle Drug Delivery SystemNeuroprotective AgentsDrug deliveryIschemic strokeNanoparticlePathophysiologyTarget therapy

Identifiers

PMID39164747
PMCPMC11337765

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.